Back to search

Article

Development of a LAG-3 Immunohistochemistry Assay for Melanoma

2022-02-26

Abstract excerpt

<h4>Aims</h4> A robust immunohistochemistry (IHC) assay was developed to detect lymphocyte-activation gene 3 (LAG-3) expression by immune cells (ICs) in tumor tissues. LAG-3 is an immuno-oncology target with demonstrable clinical benefit, and there is a need for a standardized, well-characterized assay to measure its expression. This study aims to describe LAG-3 scoring criteria and present the specificity, sensi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c1ce70ef-22c5-53b5-bd3e-26e75eef1198
DOI
10.1101/2022.02.25.481964
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Development of a LAG-3 Immunohistochemistry Assay for MelanomaDOI 10.1101/2022.02.25.481964
LAG ‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeuticsSemantic proximity
Gene of the month: lymphocyte-activation gene 3 (LAG-3)Semantic proximity
LAG3 and Its Ligands Show Increased Expression in High-Risk Uveal MelanomaSemantic proximity
LAG-3: from molecular functions to clinical applicationsSemantic proximity
Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination With NivolumabSemantic proximity
Characterization of a new anti-LAG3 monoclonal for immuno-oncologySemantic proximity
Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentialsSemantic proximity
Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 SamplesSemantic proximity
Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer.Semantic proximity
Understanding LAG-3 SignalingSemantic proximity
Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanomaSemantic proximity
LAG Time in the Era of Immunotherapy—New Molecular Insights Into the Immunosuppression Mechanism of Lymphocyte Activation Gene‐3Semantic proximity
Select a neighboring publication to make it the new centre.